Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Advaxis Inc (ADXSD)

Advaxis Inc (ADXSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Advaxis Inc 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 USA

www.advaxis.com P: 609-452-9813

Description:

Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.

Key Statistics

Overview:

Market Capitalization, $K 6,992
Enterprise Value, $K 6,959
Shares Outstanding, K 1,816
Annual Sales, $ 3,240 K
Annual Net Income, $ -17,860 K
Last Quarter Sales, $ 250 K
Last Quarter Net Income, $ -2,440 K
60-Month Beta 2.21
% of Insider Shareholders 0.30%
% of Institutional Shareholders 0.06%
Float, K 1,811
% Float 99.70%
Short Volume Ratio 0.02

Growth:

1-Year Return -89.80%
3-Year Return -96.92%
5-Year Return -99.95%
5-Year Revenue Growth -18.80%
5-Year Earnings Growth 99.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.90 on 06/08/22
Next Earnings Date 06/13/22
Earnings Per Share ttm -9.10
EPS Growth vs. Prev Qtr 20.83%
EPS Growth vs. Prev Year 40.63%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-80 on 06/06/22

ADXSD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -39.23%
Return-on-Assets % -33.85%
Profit Margin % -551.23%
Debt/Equity 0.00
Price/Sales 1.99
Price/Cash Flow N/A
Price/Book 0.20
Book Value/Share 19.31
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar